Tenon Medical (TNON) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Steven Foster - CEO, President & DirectorKevin Williamson - Chief Financial OfficerNicholas Sherwood - Equity Research Associate Conference Call Participants Scott Henry - Managing Director & Senior Research Analyst Operator Greetings and welcome to the Tenon Medical First Quarter twenty twenty five Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are S ...

Tenon Medical (TNON) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Greetings and welcome to the Tenon Medical First Quarter twenty twenty five Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steve Foster, President and Chief Executive Officer and Kevin Williamson, Chief Financial Officer. Mr. Foster and Mr. Williamson will present results of operations for the first quarter ended 03/31/2025 and provide a corporate update. A p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ COMMISSION FILE NUMBER 001-41364 TENON MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 45-5574718 (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-41364 TENON MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 104 Cooper Court Los Ga ...

Tenon Medical (TNON) Q4 2024 Earnings Call March 20, 2025 10:35 PM ET Company Participants Steven Foster - CEO, President & DirectorKevin Williamson - Chief Financial OfficerAnthony Vendetti - Executive Managing Director Operator Greetings, and welcome to the Tenon Medical Fourth Quarter and Full Year twenty twenty four Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steve Foster, President and Chief Executive Officer and Kevin William ...

Tenon Medical, Inc. (NASDAQ:TNON) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Steve Foster - President and CEO Kevin Williamson - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Greetings. And welcome to the Tenon Medical Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your hosts today are Steve Foster, President and Chief Executive Officer; a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ COMMISSION FILE NUMBER 001-41364 TENON MEDICAL, INC. (Exact name of registrant as specified in its charter) | --- | --- | |------- ...

Financial Data and Key Metrics Changes - Revenue for Q3 2024 was $887,000, a decrease of 6% compared to $944,000 in Q3 2023. For the nine months ended September 30, 2024, revenue was $2.5 million, an increase of 18% compared to $2.1 million in the prior year period [27] - Gross profit in Q3 2024 was $418,000, or 47% of revenue, compared to $535,000 or 57% of revenue in Q3 2023. For the nine months ended September 30, 2024, gross profit was $1.4 million, or 54% of revenue, compared to $682,000 or 32% of revenue in the prior year period [29] - Net loss was $3.2 million for Q3 2024, an improvement from a net loss of $3.3 million in the same period in 2023. For the nine months ended September 30, 2024, net loss was $10.6 million, improving from $12.6 million in the previous year period [33] Business Line Data and Key Metrics Changes - Surgical procedures utilizing the Catamaran System increased by 5% for the nine months ended September 30, 2024, but decreased by 15% in Q3 2024 compared to the same quarter in the previous year [27][28] - The company introduced the Catamaran SE, a second-generation and smaller version of their implant, which is expected to enhance market share during its second year of commercialization [10][12] Market Data and Key Metrics Changes - The company experienced unexpected reimbursement preauthorization headwinds, attributed to coding confusion, which is expected to improve with upcoming coding clarity [8][39] - The company anticipates that the combination of coding clarity and new clinical data will positively impact reimbursement issues going forward [40][42] Company Strategy and Development Direction - The company is focused on building market share for the Catamaran System and securing capital to fund growth initiatives [6] - A significant component of the growth strategy includes investment in clinical research to reinforce the safety and effectiveness of the Catamaran System [14] - The company plans to expand its sales force and continue its post-market study with the publication of further analysis for the Catamaran [11][34] Management's Comments on Operating Environment and Future Outlook - Management believes that the reimbursement impacts and timing of sales force restructuring will become tailwinds moving forward [28] - The company expects to maintain momentum and is excited about the growth trajectory supported by capital resources and expanding commercial infrastructure [36] Other Important Information - The company received an investment of approximately $9.6 million during the quarter, which will be used to expand the sales force and advance the launch of the new Catamaran SE [11][34] - The U.S. Patent Office issued three patents related to the enhanced Catamaran prosthesis, strengthening the company's competitive position [23][24] Q&A Session Summary Question: What caused the unexpected reimbursement preauthorization headwinds? - Management indicated that reimbursement issues are regional and stemmed from coding confusion, which is expected to improve with clarity from recent AMA meetings [38][39] Question: How is the feedback from physicians regarding the system? - Management confirmed that feedback has been positive, leading to the development of the Catamaran SE, which is a smaller version of the system to meet varying physician preferences [43][44] Question: Is the expansion of the sales force currently underway? - Management stated that the expansion of the sales force is an active initiative and will continue over the coming months and quarters [45]

Tenon Medical, Inc. (NASDAQ:TNON) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Steven Foster - CEO and President Steven Van Dick - CFO and EVP, Finance and Administration Conference Call Participants Bruce Jackson - The Benchmark Company Anthony Vendetti - Maxim Group Operator Greetings and welcome to the Tenon Medical's Second Quarter 2024 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. Your host today are Steve Foster, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ to __________ COMMISSION FILE NUMBER 001-41364 TENON MEDICAL, INC. (Exact name of registrant as specified in its charter) | --- | --- | |------------ ...